Icecure Medical LTD. (ICCM) — SEC Filings

Overview

Icecure Medical LTD. (ICCM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 21, 2026: On April 21, 2026, IceCure Medical Ltd. filed a 6-K report. This filing includes a press release announcing the company's participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting. The press release details IceCure's presentation of its cryoablation technology for

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 16 bullish, 34 neutral. The dominant filing sentiment for Icecure Medical LTD. is neutral.

Filing Type Overview

Icecure Medical LTD. (ICCM) has filed 44 6-K, 3 EFFECT, 1 F-1, 1 424B5, 1 20-F with the SEC between Jan 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

• IceCure Medical Presents Cryoablation Tech at SIR 2026 — 6-K · Apr 21, 2026 Risk: low
  On April 21, 2026, IceCure Medical Ltd. filed a 6-K report. This filing includes a press release announcing the company's participation in the Society of Interv
• EFFECT Filing — EFFECT · Apr 13, 2026
• F-1 Filing — F-1 · Apr 1, 2026
• IceCure Medical Ltd. Files Prospectus Supplement — 424B5 · Mar 27, 2026 Risk: medium
  IceCure Medical Ltd. filed a prospectus supplement (424B5) on March 27, 2026, related to a previous registration statement. The filing concerns the offering of
• 6-K Filing — 6-K · Mar 27, 2026
• IceCure Reports Positive 5-Year Top-Line Results via 6-K Filing — 6-K · Mar 25, 2026
  IceCure Medical Ltd. filed a 6-K on March 25, 2026, to report positive 5-year top-line results, as detailed in a press release dated the same day. This filing i
• IceCure Medical's Registration Statement Declared Effective by SEC — EFFECT · Mar 25, 2026
  The SEC has declared IceCure Medical Ltd.'s registration statement (File No. 333-290046) effective as of March 24, 2026. This means the company can now proceed
• IceCure Medical Appoints Meir Peleg as New CFO — 6-K · Mar 24, 2026
  IceCure Medical Ltd. announced on March 24, 2026, the appointment of Meir Peleg as their new Chief Financial Officer (CFO). This change in leadership is signifi
• IceCure Medical Registration Statement Effective March 23, 2026 — EFFECT · Mar 24, 2026
  The SEC has declared IceCure Medical Ltd.'s registration statement (File No. 333-288062) effective as of March 23, 2026. This means the company can now proceed
• 6-K Filing — 6-K · Dec 17, 2025
• IceCure Medical's ProSense Featured in Breast Cancer Studies — 6-K · Dec 10, 2025 Risk: low
  On December 10, 2025, IceCure Medical Ltd. announced that its ProSense® Cryoablation technology was featured in four independent breast cancer studies presented
• IceCure Medical gets China patent for cryoablation tech — 6-K · Dec 5, 2025 Risk: low
  On December 5, 2025, IceCure Medical Ltd. announced it received a notice of patent allowance in China for a novel cryogen flow control system. This system is de
• IceCure Medical Ltd. Files December 2025 6-K Report — 6-K · Dec 3, 2025 Risk: low
  IceCure Medical Ltd. filed a Form 6-K on December 3, 2025, reporting for the month of December 2025. The filing includes a Notice of Meeting and Proxy Statement
• IceCure Medical Reports Q3 2025 Results — 6-K · Nov 19, 2025 Risk: low
  IceCure Medical Ltd. filed a Form 6-K on November 19, 2025, to report its financial and operational results for the nine months ended September 30, 2025. The fi
• IceCure Medical's ProSense System Approved in Switzerland — 6-K · Nov 18, 2025 Risk: low
  On November 18, 2025, IceCure Medical Ltd. announced that its ProSense® Cryoablation System received regulatory approval in Switzerland. This approval covers in
• IceCure Medical Gets Nasdaq Minimum Bid Price Warning — 6-K · Nov 14, 2025 Risk: medium
  On November 14, 2025, IceCure Medical Ltd. announced it received a notification from Nasdaq regarding its minimum bid price requirement. The company is required
• IceCure Medical Ltd. Promotes Shay Levav to COO — 6-K · Nov 10, 2025 Risk: low
  On November 5, 2025, IceCure Medical Ltd. announced the promotion of Shay Levav from Vice President of Regulatory and Quality Assurance and Clinical Application
• 6-K Filing — 6-K · Nov 3, 2025
• IceCure Medical Terminates VP of Operations — 6-K · Oct 17, 2025 Risk: low
  On October 16, 2025, IceCure Medical Ltd. notified Ms. Galit Malik, its Vice President of Operations and Services, that her employment will be terminated effect
• IceCure Medical Gets FDA Nod for Breast Cancer Treatment — 6-K · Oct 3, 2025 Risk: medium
  On October 3, 2025, IceCure Medical Ltd. announced it received FDA marketing authorization for its ProSense® cryoablation system. This authorization specificall
• IceCure Medical Presents Positive Breast Cancer Study Results — 6-K · Sep 30, 2025 Risk: low
  On September 30, 2025, IceCure Medical Ltd. announced positive results from five independent studies on its ProSense system at the European Society of Breast Im
• IceCure Medical's ProSense Featured at CIRSE 2025 — 6-K · Sep 22, 2025 Risk: low
  On September 22, 2025, IceCure Medical Ltd. announced that its ProSense system was featured at the CIRSE 2025 Annual Meeting. Four independent studies presented
• IceCure Medical Secures US Patent for XSense Cryoprobes — 6-K · Sep 18, 2025 Risk: low
  On September 18, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance for a U.S. Patent for its next-generation XSense™ Cryoprobes. This paten
• IceCure Medical Gets Israeli Approval for XSense Cryoablation System — 6-K · Sep 15, 2025 Risk: medium
  On September 15, 2025, IceCure Medical Ltd. announced it received regulatory approval in Israel for its next-generation XSense™ cryoablation system. This approv
• IceCure Medical's ProSense Shows Efficacy in Endometriosis Study — 6-K · Sep 4, 2025 Risk: medium
  On September 4, 2025, IceCure Medical Ltd. announced positive results from a study on its ProSense system for treating abdominal wall endometriosis. The study d
• IceCure Medical Ltd. Shareholders Approve All Agenda Items at Annual Meeting — 6-K · Aug 20, 2025 Risk: low
  On August 20, 2025, IceCure Medical Ltd. held its Annual and Special General Meeting of Shareholders. A quorum was present, and shareholders approved all agenda
• IceCure Medical Ltd. Files 6-K Report — 6-K · Aug 13, 2025 Risk: low
  IceCure Medical Ltd. filed a Form 6-K on August 13, 2025, reporting its unaudited interim financial results for the period ending June 30, 2025. The filing is a
• IceCure Medical Ltd. Closes Rights Offering — 6-K · Aug 1, 2025 Risk: low
  IceCure Medical Ltd. announced the closing of its Rights Offering on August 1, 2025. The subscription period for this offering expired on July 28, 2025, at 5:00
• IceCure Medical Ltd. Files July 2025 Meeting Notice — 6-K · Jul 28, 2025 Risk: low
  IceCure Medical Ltd. filed a Form 6-K on July 28, 2025, to report its Notice of Meeting and Proxy Statement for the month of July 2025. The filing is from their
• IceCure Medical's ProSense Shows 99% Recurrence-Free Rate — 6-K · Jul 25, 2025 Risk: medium
  On July 25, 2025, IceCure Medical Ltd. announced that its ProSense system was featured at the Japanese Breast Cancer Society Conference. Updated clinical data p
• IceCure Medical Ltd. Files Notice of Meeting and Proxy Statement — 6-K · Jul 16, 2025 Risk: low
  IceCure Medical Ltd. filed a Form 6-K on July 16, 2025, to report its Notice of Meeting and Proxy Statement. This filing is a routine report for foreign private
• IceCure Medical Ltd. Reports Preliminary Q2 2025 Sales — 6-K · Jul 10, 2025 Risk: medium
  IceCure Medical Ltd. reported preliminary unaudited financial information for the periods ending June 30, 2025. Product sales for the three months ended June 30
• IceCure Medical Ltd. Releases Preliminary Q2 2025 Financials — 6-K · Jul 3, 2025 Risk: low
  On July 3, 2025, IceCure Medical Ltd. announced preliminary financial results for the three and six months ended June 30, 2025. The company is a foreign private
• IceCure Medical Sets Rights Offering for Up to $10M — 6-K · Jun 25, 2025 Risk: medium
  IceCure Medical Ltd. announced on June 25, 2025, a record date for a rights offering aimed at raising up to $10 million. This offering is detailed in a press re
• IceCure Medical Secures US Patent for Cryogen Flow Control — 6-K · Jun 9, 2025 Risk: low
  On June 9, 2025, IceCure Medical Ltd. announced it received a notice of patent allowance in the U.S. for a novel cryogen flow control system. This system is des
• IceCure Medical Reports Q1 2025 Financial Results — 6-K · May 28, 2025 Risk: low
  On May 28, 2025, IceCure Medical Ltd. issued a press release detailing its first quarter 2025 financial results. The report, filed as a Form 6-K, includes infor
• IceCure Medical Secures $2M Bridge Loan — 6-K · May 21, 2025 Risk: medium
  On May 17, 2025, IceCure Medical Ltd. secured a $2,000,000 unsecured bridge loan from Epoch Partner Investments Limited. The loan agreement specifies an interes
• IceCure Medical Ltd. Shareholders Approve All Agenda Items — 6-K · May 15, 2025 Risk: low
  On May 15, 2025, IceCure Medical Ltd. held a Special General Meeting of Shareholders where all agenda items, as previously outlined in the proxy statement, were
• IceCure Medical Gets FDA Clarity on ProSense for Breast Cancer — 6-K · Apr 30, 2025 Risk: medium
  On April 30, 2025, IceCure Medical Ltd. announced a positive development with the FDA regarding the marketing authorization of its ProSense® cryoablation system
• IceCure Medical Schedules Shareholder Meeting for May 15 — 6-K · Apr 10, 2025 Risk: low
  IceCure Medical Ltd. has filed a Form 6-K on April 10, 2025, announcing a Special General Meeting of Shareholders scheduled for May 15, 2025. Shareholders of re
• IceCure Medical Ltd. Files 2024 Annual Report — 20-F · Mar 27, 2025 Risk: medium
  IceCure Medical Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is involved in the s
• IceCure Medical Updates FDA Progress for ProSense Breast Cancer Device — 6-K · Mar 20, 2025 Risk: medium
  On March 20, 2025, IceCure Medical Ltd. announced an updated timeline and progress with the FDA regarding marketing authorization for its ProSense system in ear
• IceCure Medical's ProSense Featured in Breast Cancer Studies — 6-K · Mar 18, 2025 Risk: low
  On March 18, 2025, IceCure Medical Ltd. announced that its ProSense® Cryoablation system was featured in six studies presented at the St. Gallen International B
• IceCure Medical Gets China Patent Allowance for Cryoablation Pump — 6-K · Mar 17, 2025 Risk: low
  On March 17, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance in China for its novel cryogenic pump, a key component for its next-generati
• IceCure Medical's ProSense® Shows Higher Patient Satisfaction in Japan — 6-K · Mar 10, 2025 Risk: medium
  On March 10, 2025, IceCure Medical Ltd. announced positive results from a study in Japan regarding their ProSense® cryoablation treatment for breast cancer. Pat
• IceCure Medical seeks Israeli approval for XSense cryoablation system — 6-K · Feb 24, 2025 Risk: low
  On February 24, 2025, IceCure Medical Ltd. announced it has submitted a filing for regulatory approval of its next-generation XSense™ Cryoablation System in Isr
• IceCure Medical's ProSense Featured at SIO Meeting Amid FDA Decision Anticipation — 6-K · Feb 4, 2025 Risk: medium
  On February 4, 2025, IceCure Medical Ltd. announced its ProSense system was featured at the Society of Interventional Oncology (SIO) Annual Meeting. The company
• IceCure Medical Seeks China Approval for ProSense System — 6-K · Jan 27, 2025 Risk: medium
  On January 27, 2025, IceCure Medical Ltd. announced it has filed for regulatory approval of its ProSense® Cryoablation System in China. This filing is a signifi
• IceCure Medical Reports 42% Sales Jump in North America — 6-K · Jan 13, 2025 Risk: medium
  On January 13, 2025, IceCure Medical Ltd. announced a 42% increase in ProSense® sales for 2024 in North America, as detailed in a letter from their CEO to share
• IceCure Medical Regains Nasdaq Compliance — 6-K · Jan 6, 2025 Risk: low
  On January 6, 2025, IceCure Medical Ltd. announced it has regained full compliance with the Nasdaq Stock Market's minimum closing bid price rule. This complianc

Related Companies

ICUR · ICCU

Frequently Asked Questions